Don't mean to be a wet blanket here, but a lot of biotechs kick ass in Phase II, then experience enough delays and problems in Phase III that they run out of money, or dilute beyond any profitable prospects.
I would suggest a brief study of Amilyn Pharmaceuticals, a stock that cost me a decent chunk. They were screaming along with large Phase III trials mostly paid for by Lilly. The drug, pramlintide, was going to revolutionize treatment for diabetes (and still might, someday). The first "look" at Phase III results was lukewarm-not bad really, just lukewarm. The stock went to hell, then they forced a loan from Lilly, who eventually took a walk. Some of the shareholders were even rumored to have gone insane, taking to parking on other bio threads and stalking and harrassing everyone there. I remember a time when I was thrilled to death to be able to buy Amilyn at current IMNR prices. Check out Amilyn today (McCamant just recommended it again today on CNBC, the dumb-a--!) (:-<).
Be assured, I'm not drawing any conclusions about IMNR, a company which I don't know well. But my experience with companies on the threshold of Phase III with only one main product and no short-run prospects for revenues has been mostly bad. |
